DrugPatentWatch Database Preview

Celgene Company Profile

« Back to Dashboard

What is the competitive landscape for CELGENE, and what generic alternatives to CELGENE drugs are available?

CELGENE has seven approved drugs.

There are fifty-one US patents protecting CELGENE drugs.

There are six hundred and fifty-nine patent family members on CELGENE drugs in fifty-one countries and twenty supplementary protection certificates in twelve countries.

Summary for Celgene

International Patents:	659
US Patents:	51
Tradenames:	7
Ingredients:	7
NDAs:	7
Patent Litigation for Celgene:	See patent lawsuits for Celgene
PTAB Cases with Celgene as patent owner:	See PTAB cases with Celgene as patent owner

Drugs and US Patents for Celgene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003		RX	Yes	Yes	6,561,977
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998		RX	Yes	No	6,315,720
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003		RX	Yes	No	6,045,501
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-004	Feb 8, 2013		RX	Yes	Yes	8,735,428
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006		RX	Yes	No	8,204,763

Expired US Patents for Celgene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	6,561,976
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	8,288,415
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-003	Feb 8, 2013	8,204,763
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	6,561,976
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	7,723,361

Paragraph IV (Patent) Challenges for CELGENE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	25 mg		2010-07-12
	Capsules	2.5 mg and 20 mg		2016-07-12
	Capsules	200 mg		2006-09-25
	Injection	10 mg/vial		2013-11-05
	Capsules	1 mg, 2 mg, 3 mg and 4 mg		2017-02-08
	Capsules	5 mg, 10 mg and 15 mg		2010-08-30
	Capsules	50 mg and 100 mg		2006-12-18
	Capsules	150 mg		2014-02-03
	Tablets	10 mg, 20 mg and30 mg		2018-03-22

International Patents for Celgene Drugs

Country	Document Number	Estimated Expiration
Japan	5839770
Japan	2004508049
Israel	241949
Mexico	PA04009075
African Intellectual Property Organization (OAPI)	13250

Supplementary Protection Certificates for Celgene Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
00358	Netherlands		PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
56/2007	Austria		PRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES
2007 00054	Denmark		PRODUCT NAME: LENALIDOMID, EVT. I FORM AF SYREADDITIONSSALT
C0036	France		PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
C/GB08/039	United Kingdom		PRODUCT NAME: THALIDOMIDE (INTERNATIONAL NON-PROPRIETARY NAME) 2-(2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLINE-1,3-DIONE (SYSTEMATIC (IUPAC) NAME); REGISTERED: UK EU/1/08/443/001 20080416

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Celgene
• Celgene Corp